Older Age But Not Comorbidity is Associated with Worse Survival in Patients with Hepatocellular Carcinoma

Age and comorbidity are key factors in assessing patient prognosis and informing stopping rules for cancer screening eligibility, but their impact has not been rigorously evaluated in patients with hepatocellular carcinoma (HCC). We conducted a retrospective cohort study of patients diagnosed with HCC at 2 health systems between January 2010 and February 2023. We used multivariable logistic regression and Cox proportional hazards models to evaluate the associations between older age (≥65 years) and comorbidity burden (Charlson Comorbidity Index) with early stage presentation, curative treatment receipt, and overall survival. We performed subgroup analyses in patients with early stage HCC. We identified 2002 patients with HCC (median age, 61 years; 76% male; 21% early stage), with a median survival of 15.7 months. In adjusted analyses, curative treatment receipt was associated with higher comorbidity but not older age. Conversely, overall survival was significantly associated with older age (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.06–1.47) but not high comorbidity (HR, 0.92; 95% CI, 0.77–1.09). Older age continued to be associated with worse survival among patients with early stage HCC (HR, 1.99; 95% CI, 1.45–2.73) and those who underwent curative treatment (HR, 1.52; 95% CI, 1.10–2.10). Median survival for younger versus older individuals was 20 versus 14 months overall, 65 versus 49 months for patients with early stage HCC, and 113 versus 60 months for those with curative treatment. Older age but not comorbidity burden is associated with worse survival in patients with early stage HCC. Further studies are needed to define the role of comorbidity in HCC prognostication.